Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients-Reference-Cited by-同舟云学术

Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients

Published:2015-11 Issue:21 Volume:11 Page:2881-2891
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Conteduca Vincenza¹,Caffo Orazio²,Fratino Lucia³,Lo Re Giovanni⁴,Basso Umberto⁵,D'Angelo Alessandro⁶,Donini Maddalena⁷,Verderame Francesco⁸,Ratta Raffaele⁹,Procopio Giuseppe¹⁰,Campadelli Enrico¹¹,Massari Francesco¹²,Gasparro Donatello¹³,Ermacora Paola¹⁴,Messina Caterina¹⁵,Giordano Monica¹⁶,Alesini Daniele¹⁷,Zagonel Vittorina⁵,Veccia Antonello²,Lolli Cristian¹,Maines Francesca²,De Giorgi Ugo¹

Affiliation:

1. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

2. Santa Chiara Hospital, Trento, Italy

3. National Cancer Center CRO, Aviano, Italy

4. Santa Maria Degli Angeli General Hospital, Pordenone, Italy

5. Medical Oncology Unit I, Department of Clinical & Experimental Oncology Istituto Oncologico Veneto IOV, IRCCS, Padova, Italy

6. S Vincenzo Hospital, Taormina, Italy

7. Istituti Ospitalieri di Cremona, Cremona, Italy

8. Medical Oncology, Azienda Ospedaliera Villa Sofia-Cervello, Palermo, Italy

9. Campus Bio-Medico University of Rome, Rome, Italy

10. Oncology Unit I, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

11. Civil Hospital, Lugo di Romagna, Italy

12. Institut Gustave Roussy, Villejuif, France

13. University Hospital of Parma, Parma, Italy

14. Dipartimento di Oncologia, Azienda Ospedaliero-Universitaria, Udine, Italy

15. Medical Oncology Unit, Piazza OMS, 1, Pope John Paul XXIII Hospital, Bergamo, Italy

16. Santa Anna Hospital, Como, Italy

17. Division of Medical Oncology, Università la Sapienza Roma, Rome, Italy

Abstract

Background: The objective of this study was to analyze the impact of visceral metastases in castration-resistant prostate cancer (CRPC) treated with abiraterone. Materials & methods: All CRPC patients received abiraterone 1000 mg daily plus prednisone 10 mg orally daily. Liver and lung metastases were considered as visceral metastases. Results: Of 265 CRPC patients, 49 had visceral metastases. Results on progression-free survival were not significantly different in patients with or without visceral metastases. Conversely, the median overall survival between the two groups was 12.4 and 18.5 months (p = 0.01), respectively, and median overall survival of patients with liver-only disease versus other sites was 10.5 versus 18.5 months (p = 0.006), respectively. Conclusion: Visceral disease appears to be an important predictor of clinical outcome in CRPC patients treated with abiraterone.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon.15.158

Reference38 articles.

1. Cancer statistics, 2015

2. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

3. Visceral metastases in prostate cancer: an underestimated and understudied subgroup

4. Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies

5. Aggressive Variants of Castration-Resistant Prostate Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies;Cancers;2024-05-30

2. From biology to the clinic — exploring liver metastasis in prostate cancer;Nature Reviews Urology;2024-04-26

3. Metastasis-Directed Therapy for Metachronous Lung Metastases in Prostate Cancer;JU Open Plus;2023-10

4. Liver Microenvironment Response to Prostate Cancer Metastasis and Hormonal Therapy;Cancers;2022-12-15

5. Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study;European Journal of Cancer;2022-02